Nevro Corp (1N7.BE)
| Previous close | 8.65 |
| Open | 8.55 |
| Bid | 8.55 x N/A |
| Ask | 8.60 x N/A |
| Day's range | 8.55 - 8.55 |
| 52-week range | 8.45 - 24.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 30 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyHere’s Why Nevro Corp. (NVRO) Shares Detracted from Performance
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. US markets performed strongly in Q1, with the S&P Index up 10.56%. Investor confidence rose with the anticipated soft landing of the market. However, Class A shares […]
PR NewswireNevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on May 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 59,460 shares of Nevro's common stock to twenty-six new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Pla
Simply Wall St.Earnings Release: Here's Why Analysts Cut Their Nevro Corp. (NYSE:NVRO) Price Target To US$15.30
Nevro Corp. ( NYSE:NVRO ) investors will be delighted, with the company turning in some strong numbers with its latest...
